Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00947882 · ClinicalTrials.gov registry record · Phase 2
A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)
A Phase 2 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 404
- Enrollment target
NCT00947882: Completed Phase 2 study, sponsored by Ferring Pharmaceuticals.
NCT00947882 is a Phase 2 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 404 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (204% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00947882, a Phase 2 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 404 participants
- Enrollment target
Study Summary
A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
Primary Outcome
This outcome measure was used to assess the dose-response of the 3 degarelix dose groups in terms of severity of lower urinary tract symptoms (LUTS) and progress of the disease process, versus the placebo group. One treatment month equals 28 days. The IPSS questionnaire is a tool commonly used to assess the severity of LUTS, and to monitor the progress of the symptoms during treatment. It contains 7 questions regarding incomplete emptying, frequency, intermittency, urgency, weak stream, straini
Interventions
- DRUG Placebo
- DRUG Degarelix 10 mg
- DRUG Degarelix 20 mg
- DRUG Degarelix 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2009-08 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
What the finished NCT00947882 record still lists
NCT00947882 is an interventional study that assigns participants to a tested intervention. The registered 404 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (204% higher).
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT00947882 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00947882 about?
NCT00947882 is a clinical study titled "A Trial of Degarelix in Men With Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH)". A dose-finding, multi-centre, double-blind, randomised, parallel, placebo-controlled trial to investigate efficacy and safety of degarelix in men with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH)
What is the current status of trial NCT00947882?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 404 participants. The study started on 2009-08. Estimated completion is 2011-06.
What interventions are being tested in trial NCT00947882?
The interventions under investigation include: Placebo (DRUG), Degarelix 10 mg (DRUG), Degarelix 20 mg (DRUG), Degarelix 30 mg (DRUG).
Who is sponsoring clinical trial NCT00947882?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00947882's enrollment target sits among peer trials
404 95th of 2000 higher than 1,905 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05049057 · 404 participants · Phase 2
Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI
- NCT05611242 · 404 participants · Phase 3
Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy Trial
- NCT06072612 · 404 participants · Phase 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
- NCT05576350 · 405 participants · NA
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia